Advanced Search
KONG Yan, JIANG Da, ZHANG Min. Effect of Thal idomide on VEGF-C and Its Receptor Expression in Human Breast Cancer Cell Lines[J]. Cancer Research on Prevention and Treatment, 2007, 34(12): 921-923. DOI: 10.3971/j.issn.1000-8578.61
Citation: KONG Yan, JIANG Da, ZHANG Min. Effect of Thal idomide on VEGF-C and Its Receptor Expression in Human Breast Cancer Cell Lines[J]. Cancer Research on Prevention and Treatment, 2007, 34(12): 921-923. DOI: 10.3971/j.issn.1000-8578.61

Effect of Thal idomide on VEGF-C and Its Receptor Expression in Human Breast Cancer Cell Lines

More Information
  • Corresponding author:

    JIANG Da

  • Received Date: January 04, 2007
  • Revised Date: May 31, 2007
  • Objective  To assess the effect s of thalidomide on VEGF-C and KDR expression in human breast cancer cell lines, MCF-7 and MDA-MB-231. Methods  Breast cancer cells were treated with thalidomide, then cell proliferation were examined by the method of MTT. The level of VEGF-C mRNA expression was distinguished by semi-quantitative RT-PCR technique. Flow cytometry was applied to examine the protein expression of VEGF-C and KDR. Results  Within the concent ration of (60~120) μg/ml, thalidomide strongly inhibited proliferation of MCF27 and MDA-MB-231. When the drug is 60 μg/ml, thalidomide can inhibit the mRNA expression of VEGF-C and the protein expression of VEGF-C and KDR. Conclusion  Within a certain drug concent ration, thalidomide can inhibit human breast cancer cell proliferation. Its role of inhibiting angiogenesis maybe relate with down regulating the expression of VEGF-C and KDR.

Catalog

    Article views (2759) PDF downloads (876) Cited by()
    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return